Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

Background: Asthma is a clinical syndrome characterized by recurrent episodes of airway obstruction, bronchial hyperresponsiveness and airway inflammation. Most patients with asthma present a “type 2” (TH2) inflammation. ILC2 and TH2 cells release cytokines IL4, IL-13 and IL-5. CRSwNP is a condition...

Full description

Bibliographic Details
Main Authors: Andrea Giovanni Ledda, Giulia Costanzo, Giada Sambugaro, Cristiano Caruso, Martina Bullita, Maria Luisa Di Martino, Paolo Serra, Davide Firinu, Stefano Del Giacco
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Life
Subjects:
asthma
nasal polyps
eosinophils cationic protein
dupilumab
biomarkers
type 2 inflammation
Online Access:https://www.mdpi.com/2075-1729/13/9/1884

Internet

https://www.mdpi.com/2075-1729/13/9/1884

Similar Items